We are live on ! Find out more
CCCC icon

C4 Therapeutics
CCCC

101 hedge funds and large institutions have $153M invested in C4 Therapeutics in 2025 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 44 increasing their positions, 19 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

386% more call options, than puts

Call options by funds: $738K | Put options by funds: $152K

132% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 19

50% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 16

31% more capital invested

Capital invested by funds: $117M → $153M (+$35.9M)

8.57% more ownership

Funds ownership: 73.82% → 82.39% (+8.6%)

4% more funds holding

Funds holding: 97 → 101 (+4)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
101
Holders Change
+4
Holders Change %
+4.12%
% of All Funds
1.23%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
24
Increased
44
Reduced
19
Closed
16
Calls
$738K
Puts
$152K
Net Calls
+$586K
Net Calls Change
+$425K

Top Buyers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$22.4M
2
RCM
RA Capital Management
Massachusetts
+$19M
3
BCLSI
Bain Capital Life Sciences Investors
Massachusetts
+$14.4M
4
Morgan Stanley
Morgan Stanley
New York
+$9.5M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$2.99M

Top Sellers

1
O
OrbiMed
New York
-$9.07M
2
SCM
Soleus Capital Management
Connecticut
-$7.7M
3
TCM
Tang Capital Management
California
-$2M
4
Millennium Management
Millennium Management
New York
-$1.77M
5
WA
Wasatch Advisors
Utah
-$1.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
SFI
51
Susquehanna Fundamental Investments
Pennsylvania
$129K – – –
CAG
52
Crestwood Advisors Group
Massachusetts
$127K – – –
ECM
53
ExodusPoint Capital Management
New York
$119K +$147K +62,165 New
IFO
54
Intrepid Family Office
Florida
$105K -$35.5K -15,000 -21%
D.E. Shaw & Co
55
D.E. Shaw & Co
New York
$101K +$97.2K +41,016 +346%
UBS Group
56
UBS Group
Switzerland
$101K -$21.1K -8,898 -14%
Citigroup
57
Citigroup
New York
$95.2K +$110K +46,576 +1,427%
Corient Private Wealth
58
Corient Private Wealth
Florida
$81.7K +$47.5K +20,072 +88%
CFM
59
Catalyst Funds Management
Australia
$81.2K – – –
Group One Trading
60
Group One Trading
Illinois
$74.5K +$62.9K +26,562 +214%
Focus Partners Wealth
61
Focus Partners Wealth
Massachusetts
$72.9K +$90.5K +38,187 New
Connor, Clark & Lunn Investment Management (CC&L)
62
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$72K +$89.4K +37,721 New
JFG
63
Jefferies Financial Group
New York
$67.5K -$6.78K -2,860 -7%
LIP
64
Lighthouse Investment Partners
Florida
$64.3K +$79.7K +33,660 New
CFO
65
Callan Family Office
Pennsylvania
$60.6K +$75.2K +31,743 New
Simplex Trading
66
Simplex Trading
Illinois
$58.6K +$54.1K +22,822 +291%
Canada Pension Plan Investment Board
67
Canada Pension Plan Investment Board
Ontario, Canada
$56.3K +$69.9K +29,500 New
FCM
68
Farallon Capital Management
California
$53.5K – – –
TRCT
69
Tower Research Capital (TRC)
New York
$49.6K +$41.6K +17,566 +209%
CAM
70
Cresset Asset Management
Illinois
$47.8K – – –
EGM
71
Engineers Gate Manager
New York
$46.6K +$19.3K +8,130 +50%
VF
72
Virtu Financial
New York
$39K +$48.9K +20,655 New
DIM
73
Delta Investment Management
California
$38.2K +$47.4K +20,000 New
EL
74
EWA LLC
Pennsylvania
$32.3K -$6.21K -2,621 -13%
CUAMC
75
China Universal Asset Management Company
China
$30.2K +$7.86K +3,317 +27%
1 2
3
4 5

CCCC Hedge Fund Activity: Q4 2025 in Review

101 of the 8,223 institutional investors tracked by Wall St. Rank reported a position in C4 Therapeutics (CCCC) for Q4 2025, worth a combined $153M — up 31% from $117M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new CCCC positions and 16 closed out — a net gain of 8 holders — while 44 added to existing stakes and 19 trimmed.

The largest buyer was Point72 Asset Management, opening a new position worth an estimated $22.4M. The largest seller was OrbiMed, cutting an estimated $9.07M.

  • 101 institutional investors held C4 Therapeutics (CCCC) as of Q4 2025, up from 97 in Q3 2025.
  • Funds reported $153M of C4 Therapeutics stock for Q4 2025, up 31% quarter-over-quarter.
  • 24 funds opened new C4 Therapeutics positions in Q4 2025 and 16 closed out, a net change of +8 holders.
  • The largest C4 Therapeutics buyer in Q4 2025 was Point72 Asset Management, an estimated $22.4M added.
  • The largest C4 Therapeutics seller in Q4 2025 was OrbiMed, an estimated $9.07M sold.

Based on aggregated 13F filings for Q4 2025.